ProCE Banner Series

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Join us either in-person or online for this satellite symposium that will provide expert perspectives on how to improve the utilization of PARP inhibitor (PARPi) combination therapies for patients with metastatic castration-resistant prostate cancer by aligning clinical practice with recent data and expert recommendations and incorporating management of PARPi-associated adverse events.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This activity is intended for oncologists and other healthcare professionals caring for patients with metastatic castration-resistant prostate cancer.

All Events

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Upcoming Events

May

30

2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to elevate learners' knowledge and competence in applying PARP inhibitor-based treatment strategies to improve patient outcomes with mCRPC. By deepening their utilization of biomarkers in guiding PARPi selection, aligning clinical practice with recent data and best practices, and managing PARPi-associated adverse events, learners will be better equipped to make informed clinical decisions that enhance patient outcomes and tailor care to individual patient needs.

Target Audience
This activity is intended for oncologists and other healthcare professionals caring for patients with metastatic castration-resistant prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement best practices in testing and interpreting results, including DNA damage repair alterations, understanding the application to therapy selection

  • Describe the medical need and rationale for PARP inhibitors and PARP inhibitor-based combinations in mCRPC, evaluating clinical data 

  • Initiate therapy with PARP inhibitor-based combination regimens for the treatment of patients with prostate cancer, taking into account recent guideline updates, expert recommendations, and recent data, including patient subgroup data

  • Appropriately mitigate and manage adverse events associated with PARP inhibitor combination regimens to improve quality of life, adherence, and outcomes in patients with prostate cancer

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png
 

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by a grant from Pfizer Inc.